Coadministration of liposomal amphotericin B and contrast medium does not increase risk of kidney injury

John C. O’Horo, Douglas R. Osmon, Omar M. Abu Saleh, Jasmine R. Marcelin, Kamel A. Gharaibeh, Abdurrahman M. Hamadah, Amelia K. Barwise, Bryce M. Kayhart, Jennifer S. McDonald, Robert J. McDonald, Nelson Leung

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Intravenous radiographic contrast medium and amphotericin B are commonly required in the care of patients with fungal infections. Both interventions have proposed nephrotoxicity through similar mechanisms. We systematically examined patients who received coadministration of liposomal amphotericin B (AmBisome; GE Healthcare) and intravenous contrast medium within a 24-h period and compared the results for those patients with the results for patients who underwent noncontrast medium studies. We found 114 cases and 85 controls during our study period. Overall, no increased risk of renal injury was seen with coadministration of these 2 agents. Adjustment for age, baseline kidney function, and other clinical factors through propensity score adjustment did not change this result. Our observations suggest that, when clinically indicated, coadministration of contrast medium and liposomal amphotericin B does not present excess risk compared with that from the administration of liposomal amphotericin B alone.

Original languageEnglish (US)
Article numbere00323
JournalAntimicrobial Agents and Chemotherapy
Volume61
Issue number8
DOIs
StatePublished - Aug 2017

Fingerprint

Contrast Media
Kidney
Wounds and Injuries
Propensity Score
Mycoses
Amphotericin B
Patient Care
Delivery of Health Care
liposomal amphotericin B

Keywords

  • Computed tomography
  • Invasive fungal infection
  • Kidney injury

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Coadministration of liposomal amphotericin B and contrast medium does not increase risk of kidney injury. / O’Horo, John C.; Osmon, Douglas R.; Abu Saleh, Omar M.; Marcelin, Jasmine R.; Gharaibeh, Kamel A.; Hamadah, Abdurrahman M.; Barwise, Amelia K.; Kayhart, Bryce M.; McDonald, Jennifer S.; McDonald, Robert J.; Leung, Nelson.

In: Antimicrobial Agents and Chemotherapy, Vol. 61, No. 8, e00323, 08.2017.

Research output: Contribution to journalArticle

O’Horo, JC, Osmon, DR, Abu Saleh, OM, Marcelin, JR, Gharaibeh, KA, Hamadah, AM, Barwise, AK, Kayhart, BM, McDonald, JS, McDonald, RJ & Leung, N 2017, 'Coadministration of liposomal amphotericin B and contrast medium does not increase risk of kidney injury', Antimicrobial Agents and Chemotherapy, vol. 61, no. 8, e00323. https://doi.org/10.1128/AAC.00323-17
O’Horo, John C. ; Osmon, Douglas R. ; Abu Saleh, Omar M. ; Marcelin, Jasmine R. ; Gharaibeh, Kamel A. ; Hamadah, Abdurrahman M. ; Barwise, Amelia K. ; Kayhart, Bryce M. ; McDonald, Jennifer S. ; McDonald, Robert J. ; Leung, Nelson. / Coadministration of liposomal amphotericin B and contrast medium does not increase risk of kidney injury. In: Antimicrobial Agents and Chemotherapy. 2017 ; Vol. 61, No. 8.
@article{97f249807602448881fc47fb5e7fc0e6,
title = "Coadministration of liposomal amphotericin B and contrast medium does not increase risk of kidney injury",
abstract = "Intravenous radiographic contrast medium and amphotericin B are commonly required in the care of patients with fungal infections. Both interventions have proposed nephrotoxicity through similar mechanisms. We systematically examined patients who received coadministration of liposomal amphotericin B (AmBisome; GE Healthcare) and intravenous contrast medium within a 24-h period and compared the results for those patients with the results for patients who underwent noncontrast medium studies. We found 114 cases and 85 controls during our study period. Overall, no increased risk of renal injury was seen with coadministration of these 2 agents. Adjustment for age, baseline kidney function, and other clinical factors through propensity score adjustment did not change this result. Our observations suggest that, when clinically indicated, coadministration of contrast medium and liposomal amphotericin B does not present excess risk compared with that from the administration of liposomal amphotericin B alone.",
keywords = "Computed tomography, Invasive fungal infection, Kidney injury",
author = "O’Horo, {John C.} and Osmon, {Douglas R.} and {Abu Saleh}, {Omar M.} and Marcelin, {Jasmine R.} and Gharaibeh, {Kamel A.} and Hamadah, {Abdurrahman M.} and Barwise, {Amelia K.} and Kayhart, {Bryce M.} and McDonald, {Jennifer S.} and McDonald, {Robert J.} and Nelson Leung",
year = "2017",
month = "8",
doi = "10.1128/AAC.00323-17",
language = "English (US)",
volume = "61",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - Coadministration of liposomal amphotericin B and contrast medium does not increase risk of kidney injury

AU - O’Horo, John C.

AU - Osmon, Douglas R.

AU - Abu Saleh, Omar M.

AU - Marcelin, Jasmine R.

AU - Gharaibeh, Kamel A.

AU - Hamadah, Abdurrahman M.

AU - Barwise, Amelia K.

AU - Kayhart, Bryce M.

AU - McDonald, Jennifer S.

AU - McDonald, Robert J.

AU - Leung, Nelson

PY - 2017/8

Y1 - 2017/8

N2 - Intravenous radiographic contrast medium and amphotericin B are commonly required in the care of patients with fungal infections. Both interventions have proposed nephrotoxicity through similar mechanisms. We systematically examined patients who received coadministration of liposomal amphotericin B (AmBisome; GE Healthcare) and intravenous contrast medium within a 24-h period and compared the results for those patients with the results for patients who underwent noncontrast medium studies. We found 114 cases and 85 controls during our study period. Overall, no increased risk of renal injury was seen with coadministration of these 2 agents. Adjustment for age, baseline kidney function, and other clinical factors through propensity score adjustment did not change this result. Our observations suggest that, when clinically indicated, coadministration of contrast medium and liposomal amphotericin B does not present excess risk compared with that from the administration of liposomal amphotericin B alone.

AB - Intravenous radiographic contrast medium and amphotericin B are commonly required in the care of patients with fungal infections. Both interventions have proposed nephrotoxicity through similar mechanisms. We systematically examined patients who received coadministration of liposomal amphotericin B (AmBisome; GE Healthcare) and intravenous contrast medium within a 24-h period and compared the results for those patients with the results for patients who underwent noncontrast medium studies. We found 114 cases and 85 controls during our study period. Overall, no increased risk of renal injury was seen with coadministration of these 2 agents. Adjustment for age, baseline kidney function, and other clinical factors through propensity score adjustment did not change this result. Our observations suggest that, when clinically indicated, coadministration of contrast medium and liposomal amphotericin B does not present excess risk compared with that from the administration of liposomal amphotericin B alone.

KW - Computed tomography

KW - Invasive fungal infection

KW - Kidney injury

UR - http://www.scopus.com/inward/record.url?scp=85026373333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026373333&partnerID=8YFLogxK

U2 - 10.1128/AAC.00323-17

DO - 10.1128/AAC.00323-17

M3 - Article

C2 - 28533242

AN - SCOPUS:85026373333

VL - 61

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 8

M1 - e00323

ER -